Sign In
Buy RPRX
$53.57
+0.610 (+1.15%)
At Close: Jun 22, 2026
Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 20,000 Shares of Stock
04:54am, Tuesday, 30'th Dec 2025
Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) EVP Marshall Urist sold 20,000 shares of the business's stock in a transaction that occurred on Friday, December 26th. The shares were sold at an av
Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones
04:40pm, Monday, 29'th Dec 2025
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired the final portion of PTC Therapeutics' remaining royalty on Roche's Evrysdi for $240
George Lloyd Sells 79,346 Shares of Royalty Pharma (NASDAQ:RPRX) Stock
04:02am, Sunday, 21'st Dec 2025
Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) EVP George Lloyd sold 79,346 shares of the firm's stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $
Marshall Urist Sells 20,000 Shares of Royalty Pharma (NASDAQ:RPRX) Stock
04:44am, Friday, 19'th Dec 2025
Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) EVP Marshall Urist sold 20,000 shares of Royalty Pharma stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of
Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million
07:15am, Tuesday, 16'th Dec 2025
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an und
$500 Million for Founders… $500 for Families
12:00am, Monday, 08'th Dec 2025
Eye-opening wealth data… a replay of this morning's "American Dream 2.0" Summit… where the government might point its investment firehose next… Eric Fry says where to invest beyond "AI"
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
07:10am, Thursday, 04'th Dec 2025
NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic roya
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
07:00am, Thursday, 04'th Dec 2025
SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royal
Royalty Pharma plc (RPRX) Presents at Evercore 8th Annual Healthcare Conference Transcript
06:13pm, Wednesday, 03'rd Dec 2025
Royalty Pharma plc (RPRX) Presents at Evercore 8th Annual Healthcare Conference Transcript
Royalty Pharma plc (RPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
05:33pm, Tuesday, 02'nd Dec 2025
Royalty Pharma plc (RPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Creative Planning Buys 9,718 Shares of Royalty Pharma PLC $RPRX
04:02am, Thursday, 27'th Nov 2025
Creative Planning raised its stake in Royalty Pharma PLC (NASDAQ: RPRX) by 22.7% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). Th
Royalty Pharma to Present at Upcoming Investor Conferences
08:15am, Wednesday, 26'th Nov 2025
NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December:
Royalty Pharma PLC $RPRX Stake Reduced by Envestnet Asset Management Inc.
04:23am, Sunday, 16'th Nov 2025
Envestnet Asset Management Inc. trimmed its stake in Royalty Pharma PLC (NASDAQ: RPRX) by 6.0% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 97,612 sh
Royalty Pharma: Guidance Raised Again, Platform Strength Intact -- Buy Reiterated
07:12am, Saturday, 15'th Nov 2025
Royalty Pharma is reiterated as a Buy, supported by strong Q3 results, raised guidance, and disciplined capital deployment. The company trades at a notable discount to biopharma peers despite robust F
Royalty Pharma plc (RPRX) Q3 2025 Earnings Call Transcript
01:01pm, Wednesday, 05'th Nov 2025
Royalty Pharma plc ( RPRX ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants George Grofik - Senior VP and Head of Investor Relations & Communications Pablo Legorreta - Founder,
